Erythropoietin mediated bone formation is regulated by mTOR signaling by Kim, Jinkoo et al.
Erythropoietin Mediated Bone Formation Is Regulated by
mTOR Signaling
Jinkoo Kim,1 Younghun Jung,1 Hongli Sun,2 Jeena Joseph,1 Anjali Mishra,1,2
Yusuke Shiozawa,1 Jingcheng Wang,1 Paul H. Krebsbach,2 and Russell S. Taichman1*
1Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan
2Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor, Michigan
ABSTRACT
The role of erythropoietin (Epo) and Epo/Epo receptor (EpoR) signaling pathways for production of red blood cells are well established.
However, little is known about Epo/EpoR signaling in non-hematopoietic cells. Recently, we demonstrated that Epo activates JAK/STAT
signaling in hematopoietic stem cells (HSCs), leading to the production of bone morphogenetic protein 2 (BMP2) and bone formation and that
Epo also directly activates mesenchymal cells to form osteoblasts in vitro. In this study, we investigated the effects of mTOR signaling on Epo-
mediated osteoblastogenesis and osteoclastogenesis. We found that mTOR inhibition by rapamycin blocks Epo-dependent and -independent
osteoblastic phenotypes in human bone marrow stromal cells (hBMSCs) and ST2 cells, respectively. Furthermore, we found that rapamycin
inhibits Epo-dependent and -independent osteoclastogenesis in mouse bone marrow mononuclear cells and Raw264.7 cells. Finally, we
demonstrated that Epo increases NFATc1 expression and decreases cathepsin K expression in an mTOR-independent manner, resulting in an
increase of osteoclast numbers and a decrease in resorption activity. Taken together, these results strongly indicate that mTOR signaling plays
an important role in Epo-mediated bone homeostasis. J. Cell. Biochem. 113: 220–228, 2012.  2011 Wiley Periodicals, Inc.
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E rythropoietin (Epo) is a glycoprotein hormone that regulatesred blood cell production in the bone marrow. Under hypoxic
conditions, Epo is produced mainly by the adult kidney and secreted
Epo binds to the Epo receptor (EpoR) expressed by erythroid
progenitor cells in the marrow to stimulate proliferation, differenti-
ation, and survival [Richmond et al., 2005; Szenajch et al., 2010].
Epo-mediated conformational changes to EpoR induces several
signaling pathways, including Janus kinase 2/signal transducer and
activator of transcription 3 or 5 (JAK2/STAT3 or JAK2/STAT5),
mitogen-activated protein kinase (MAPK), protein kinase C (PKC),
and phosphatidylinositol 3 kinase/Akt (PI3K/Akt) [Richmond et al.,
2005; Szenajch et al., 2010].
In the PI3K/Akt signaling pathway, activated Akt phosphorylates
and decreases the ability of tuberous sclerosis complex 2 (TSC2) to
inhibit the mammalian target of rapamycin (mTOR), resulting in the
activation of mTOR [Inoki et al., 2002]. mTOR is the catalytic subunit
of two distinct signaling complexes, mTOR complex 1 and 2
(mTORC1 and mTORC2) [Zoncu et al., 2011]. mTORC1 consists of
mTOR, raptor, deptor, mLST8, and PRAS40 [Kim et al., 2002; Vander
Haar et al., 2007; Zoncu et al., 2011]. mTORC1 activates ribosomal
S6 kinase (S6K) and inactivates eukaryotic initiation factor 4E
binding protein 1 (4EBP1), and thus stimulates protein synthesis, cell
growth, cell proliferation, and progression through the cell cycle
[Kim et al., 2002; Nojima et al., 2003; Hong et al., 2008]. Rapamycin,
a speciﬁc inhibitor of mTOR, directly binds to mTORC1 and inhibits
mTORC1 activity [Kim et al., 2002]. In contrast, mTORC2, which
contains mTOR, rictor, deptor, mLST8, and mSIN1, activates Akt and
PKCa, promoting cell survival and cytoskeleton reorganization
[Jacinto et al., 2004; Frias et al., 2006]. In addition, mTORC2 is
insensitive to rapamycin, although prolonged treatment can inhibit
mTORC2 in many cell types [Sarbassov et al., 2006].
While we previously established that Epo activates JAK/STAT
signaling in hematopoietic stem cells (HSCs), resulting in the
secretion of bone morphogenetic protein (BMP) and bone formation,
Epo also had direct effects on bone marrow stromal cell
differentiation into osteoblasts [Shiozawa et al., 2010]. Additionally,
supra-physiologic stimulation with Epo increased the number of
multinucleated osteoclasts from precursor populations without
receptor activator of nuclear factor kB-ligand (RANKL), but failed to
activate osteoclastic bone resorption [Shiozawa et al., 2010]. To
elucidate which signaling pathway contributes to the direct effects
of Epo on the differentiation of osteoblasts and osteoclasts, we
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explored the contribution of the mTOR pathway to Epo-induced
osteogenesis since recent work has suggested that mTOR signaling is
important for both osteoblastogenesis and osteoclastogenesis. Our
results demonstrate that mTOR signaling plays an important role in
both Epo-dependent and -independent bone homeostatic mechan-
isms.
MATERIALS AND METHODS
CELL CULTURES
Mouse bone marrow-derived stromal cell line ST2, human bone
marrow stromal cells (hBMSCs, Lonza, Walkersville, MD), the mouse
macrophage cell line RAW264.7, and mouse marrow mononuclear
cells (mMMCs) were grown in alpha modiﬁed Eagle’s medium
(a-MEM, Invitrogen, Carsbad, CA) supplemented with 10% heat-
inactivated fetal bovine serum and 1% penicillin/streptomycin.
ALKALINE PHOSPHATASE AND ALIZARIN RED ASSAYS
hBMSCs and ST2 cells (5 104) were seeded onto 12-well culture
plates (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ) and
cultured in 1ml of medium at least 24 h before the initiation of the
experimental conditions. Cells were treated for 2 or 3 weeks with
20U/ml rhEpo and/or 10nM rapamycin (Cell Signaling, Danvers, MA)
while cultured in osteogenic medium containing 50mg/ml ascorbic
acid (Sigma–Aldrich, St. Louis, MO), 10mM b-glycerophosphate
(Sigma–Aldrich), and 10 nM dexamethasone (Sigma–Aldrich). After
2 weeks, the cells and matrix were ﬁxed with 4% paraformaldehyde
and stained with alkaline phosphatase substrate (Sigma–Aldrich).
After 3 weeks, the cells were ﬁxed with 4% paraformaldehyde and
stained with 2% Alizarin red (Sigma–Aldrich). Quantiﬁcation of the
staining density was analyzed using Image J software (National
Institutes of Health, USA).
TARTRATE-RESISTANT ACID PHOSPHATASE (TRAP) STAINING
Bone marrow cells were ﬂushed from femurs, tibia, and humeri of
5- to 8-week-old C57BL/6 (Jackson Laboratory, Bar Harbor, ME)
with Dulbecco’s phosphate-buffered saline (D-PBS, Invitrogen).
Debris and cell aggregates were removed using a 40-mmmesh nylon
cell strainer (BD Biosciences, San Diego, CA). mMMCs were seeded
onto 24-well plates. Cells were treated for 1 week with 20U/ml
rhEpo and/or 10 nM rapamycin while cultured in a-MEM contain-
ing 50 ng/ml recombinant human receptor activator of nuclear
factor kB-ligand (rhRANKL, R&D Systems, Minneapolis, MN) and
50 ng/ml macrophage-colony stimulating factor (M-CSF, R&D
Systems). RAW264.7 was also treated for 1 week with 20U/ml rhEpo
and/or 10 nM rapamycin while cultured in a-MEM in the presence
and absence of 50 ng/ml rhRANKL. Medium was changed every 2
days. After 1 week, cells were stained by TRAP staining kit (Kamiya
Biomedical Company, Seattle, WA) according to the manufacturer’s
instructions. Numbers of TRAPþmultinucleated cells (three or more
nuclei per cell) were analyzed.
IN VITRO BONE RESORPTION ASSAYS
Bone marrow cells and RAW264.7 cells were seeded on the BioCoat
Osteologic Discs (BD Biosciences) in 24-well plates. Cells were
treated for 1 week with 20U/ml rhEpo and/or 10 nM rapamycin
while cultured in a-MEM containing 50 ng/ml rhRANKL and/or
50 ng/ml M-CSF. Medium was changed every 2 days. After 1 week,
bone resorption assays were performed according to the manu-
facturer’s instructions. The mean area of resorption from ﬁve
randomly selected ﬁelds was analyzed by Image J software.
QUANTITATIVE RT-PCR
hBMSCs and ST2 cells were treated with/without 20U/ml rhEpo for
24 h. RAW264.7 cells were treated for 5 days with 20U/ml rhEpo
and/or 10 nM rapamycin while cultured in a-MEM containing
50 ng/ml rhRANKL. Total RNA was extracted from cells using the
RNeasy mini kit (Qiagen, Valencia, CA) and converted into cDNA
using First-Strand Synthesis Kit (Invitrogen). Quantitative PCR was
carried out on ABI 7700 sequence detector (Applied Biosystems,
Forster City, CA) using TaqMan Universal PCR Master Mix Kit
(Applied Biosystems) according to the manufacturer’s instructions.
TaqMan MGB probes (Applied Biosystems) were as follows:
human EpoR (Hs00181092_m1), mouse EpoR (Mm00833882_m1),
mouse NFATc1 (Mm00479445_m1), and mouse Cathepsin K
(Mm00484036_m1). Human beta-actin (Hs99999903_m1) and
mouse beta-actin (Mm00607939_s1) were used as the internal
control for the normalization of target gene expression.
WESTERN BLOTS
Whole cell lysates were prepared from cells, separated on 10%
SDS–polyacrylamide gel and transferred to PVDF membrane. The
membranes were incubated with 5%milk for 1 h and incubated with
primary antibodies overnight at 48C. Primary antibodies used were
as follows: polyclonal anti-phospho-Akt (1:1,000; Cell Signaling),
polyclonal anti-phospho-S6 (Ser240/244) (1:4,000; Cell Signaling),
polyclonal anti-S6 (1:4,000; Cell Signaling). Blots were incubated
with peroxidase-coupled secondary antibodies (Promega, Madison,
WI) for 1 h, and protein expression was detected with SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientiﬁc, Rock-
ford, IL). Membranes were reprobed with polyclonal anti-b-actin
antibody (1:1,000; Cell Signaling) to control for equal loading.
STATISTICAL ANALYSES
Results are presented as mean standard deviation of mean.
Signiﬁcance of the difference between two measurements was
determined by unpaired Student’s t-test, and multiple comparisons
were evaluated by the Newman–Keuls multiple comparison test.
Values of P< 0.05 were considered signiﬁcant.
RESULTS
RAPAMYCIN INHIBITS EPO-DEPENDENT AND -INDEPENDENT
OSTEOBLASTIC PHENOTYPE IN HUMAN BONE MARROW
STROMAL CELLS AND ST2 CELLS
Recently, we found that Epo can regulate bone formation in vitro
and in vivo [Shiozawa et al., 2010]. To determine if the mTOR
signaling pathway is involved in Epo-mediated bone formation, we
used rapamycin, a well known and speciﬁc inhibitor of mTOR.
Epo induced differentiation and mineralization of hBMSCs as
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determined by ALP staining (Fig. 1A) and Alizarin red staining
(Fig. 1B). In contrast, Epo did not induce differentiation and
mineralization of ST2 cells (Fig. 2A,B). However, rapamycin
strongly blocked osteoblast differentiation in both cell types
(Figs. 1A,B and 2A,B). Western blot analysis showed that Epo can
activate Akt and mTOR signaling in both cells and that rapamycin
can block Epo-mediated mTOR activation in both cells as
demonstrated by the reduction in pAkt and pS6 levels
(Figs. 1C and 2C). EpoR mRNA expression was examined by
quantitative RT-PCR in hBMSCs and ST2 cells. EpoR mRNA
expression was signiﬁcantly increased in hBMSCs upon the Epo
treatment (Fig. 1D). However, EpoR mRNA expression did
not respond to Epo in ST2 cells (Fig. 2D). These data suggest that
mTOR signaling is essential for Epo-dependent and -independent
osteoblastic differentiation.
RAPAMYCIN INHIBITS EPO-DEPENDENT AND -INDEPENDENT
OSTEOCLASTOGENESIS IN MOUSE MARROW MONONUCLEAR
CELLS AND RAW264.7 CELLS
We previously reported that Epo induces osteoclast formation, but
not osteoclast activity [Shiozawa et al., 2010]. To investigate the
effect of rapamycin on EPO-mediated osteoclastogenesis, mMMCs
were treated for 1 week with or without RANKL, Epo, and rapamycin
in medium containing M-CSF. As expected, RANKL induced
osteoclast formation (Fig. 3A,B) and Epo in combination with
RANKL increased the number of osteoclasts (Fig. 3A,B), but
decreased osteoclast activity (Fig. 3C,D). In contrast, mTOR
inhibition by rapamycin robustly induced cell death (Fig. 3A) and
blocked the induction of an osteoclastic phenotype in mouse bone
marrow mononuclear cells (Fig. 3A–D). In RAW264.7 cells,
rapamycin treatment did not affect cell death (Fig. 4A), but
Fig. 1. Rapamycin inhibits Epo-dependent osteoblast differentiation in hBMSC. hBMSC were cultured in differentiation inducing media containing Epo and/or rapamycin and
assayed via alkaline phosphatase staining after 2 weeks (A) and Alizarin red staining after 3 weeks (B). Staining was quantiﬁed using Image J software and normalized to cell
number. The experiments were performed twice. C: Protein extracts from hBMSC cells were analyzed by Western blotting using antibodies against the indicated proteins.
D: hBMSC cells were treated for 24 h with/without Epo. Expression of EpoR was quantiﬁed by qPCR. The results were normalized to b-actin. The results represent average values
from triplicate assays and the experiments were performed twice.
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signiﬁcantly decreased osteoclast formation by RANKL and/or Epo
(Fig. 4A,B) and osteoclast activity on bone resorption (Fig. 4C,D).
These data suggest that mTOR signaling is also important for Epo-
dependent and -independent osteoclastic phenotype.
EPO INCREASES NFATc1 EXPRESSION AND DECREASES CATHEPSIN
K EXPRESSION IN AN mTOR-INDEPENDENT MANNER
Because it is not known how Epo increases the number of osteoclasts
yet fails to activate these cells, we investigated the down-stream
target genes that Epo regulates during osteoclastogenesis.
RAW264.7 cells were treated for 5 days with Epo and/or rapamycin
in medium in the presence and absence of RANKL. Quantitative PCR
revealed that both Epo and rapamycin treatments increased in
NFATc1 mRNA which regulates osteoclast fusion in the presence of
RANKL (Fig. 5A). Conversely, both Epo and rapamycin were able to
decrease the expression of cathepsin K which is involved in
osteoclast-mediated bone resorption (Fig. 5B). These data suggest
that Epo increases the number of osteoclasts by up-regulation of
NFATc1 while at the same time decreases their activity by down-
regulation of cathepsin K in an mTOR-independent manner. Taken
together, these results strongly indicate that mTOR signaling plays
an important role in Epo-dependent and -independent bone
formation.
DISCUSSION
Emerging evidence demonstrates that mTOR signaling plays an
important role in bone formation [Niziolek et al., 2009; Phorn-
phutkul et al., 2009; Sanchez and He, 2009]. Here, we investigated
the role of mTOR signaling in Epo-mediated differentiation of
osteoblasts and osteoclasts. We found that Epo directly induces the
Fig. 2. Rapamycin inhibits Epo-independent osteoblast differentiation in ST2 cells. ST2 cells were cultured in differentiation inducing media containing Epo and/or rapamycin
and assayed via alkaline phosphatase staining after 2 weeks (A) and Alizarin red staining after 3 weeks (B). Staining was quantiﬁed using Image J software and normalized to cell
number. The experiments were performed twice. C: Protein extracts from ST2 cells were analyzed byWestern blotting using antibodies against the indicated proteins. D: ST2 cells
were treated for 24 h with/without Epo. Expression of EpoR was quantiﬁed by qPCR. The results were normalized to b-actin. The results represent average values from triplicate
assays and the experiments were performed twice.
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differentiation of hBMSCs into osteoblasts and that mTOR inhibition
by rapamycin blocks osteoblast differentiation. These results suggest
that mTOR signaling pathway is necessary for Epo-mediated
osteoblastic differentiation of hBMSCs. However, Epo was unable
to induce differentiation of the mouse bone marrow-derived stromal
cell line ST2. Interestingly, rapamycin blocks Akt phosphorylation
induced by Epo in hBMSC, but has little effect on ST2 cells, although
rapamycin totally blocks Epo-mediated S6 phosphorylation in both
cells (Figs. 1C and 2C). These ﬁndings indicate that ST2 cells may be
more dependent on rapamycin-insensitive mTORC2, rather than
rapamycin-sensitive mTORC1. Moreover, we found that Epo
increases the expression of EpoR in hBMSC but fails to induce
EpoR in ST2 cells, although both cell types express EpoR at the
same level (Figs. 1D and 2D). Nevertheless, rapamycin blocks the
osteoblastic differentiation of ST2 cells, suggesting that the mTOR
pathway is also necessary for Epo-independent osteoblastic
differentiation of ST2.
We also found that Epo in combination with RANKL increases the
number of osteoclasts generated from mMMCs and from RAW264.7
cells, and that rapamycin inhibits Epo-mediated osteoclast forma-
tion in both cell types. However, Epo inhibits the activity of
osteoclasts by down-regulation of cathepsin K in an mTOR-
independent manner. In osteoblastogenesis, mTOR signaling may
affect the proliferation and differentiation of osteoblasts. However,
the effect of rapamycin on osteoblast differentiation remains
controversial. Rapamycin promotes the osteoblastic differentiation
of human embryonic stem cells by blocking the mTOR pathway and
stimulating the BMP/Smad pathway [Lee et al., 2010]. Moreover,
NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, also
promotes osteogenic differentiation in human mesenchymal
stromal cells [Martin et al., 2010]. In mouse bone marrow-derived
stromal cell line ST2, rapamycin increases osteoprotegerin (OPG)/
osteoclastogenesis inhibitory factor, which is a soluble decoy
receptor for osteoclast differentiation factor as well as RANKL [Mogi
Fig. 3. Rapamycin inhibits Epo-dependent and -independent osteoclastogenesis in mouse marrow mononuclear cells. Mouse marrow mononuclear cells (mMMCs) were
treated with Epo and/or rapamycin while cultured in media with/without RANKL (or RL) and M-CSF. After 1 week, TRAP staining was performed. A: Representative micrographs
of TRAP-positive osteoclast. Original magniﬁcation at 20. B: The numbers of TRAP-positive osteoclast were scored. The results represent average values from triplicate assays
and the experiments were performed twice. C: Representative micrographs of bone resorption. Original magniﬁcation at 20. D: Resorption area from ﬁve randomly selected
ﬁelds was quantiﬁed using Image J software.
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and Kondo, 2009]. In contrast, rapamycin inhibits osteoblast
proliferation and differentiation in MC3T3-E1 cells and primary
mouse bone marrow stromal cells [Singha et al., 2008]. In rat bone
marrow stromal cells, rapamycin inhibits the effect of osteogenic
differentiation induced by dexamethasone [Isomoto et al., 2007]. In
fetal rat calvaria cells, the inhibition of p70S6 kinase by rapamycin
blocks osteogenic protein-1 induction of alkaline phosphatase
activity [Shoba and Lee, 2003].
In osteoclastogenesis, mTOR signaling regulates survival and
differentiation of osteoclasts. Glantschnig et al. [2003] reported that
rapamycin blocks M-CSF- and RANKL-dependent osteoclast
survival, resulting in apoptosis. mTOR knock-down using siRNA
gene silencing also induces apoptosis through increase of Bim, a
proapoptotic Bcl-2 family member and completely blocked
osteoclast formation [Sugatani and Hruska, 2005]. Furthermore,
mTOR regulates osteoclast differentiation by modulating the
C/EBPb isoform ratio and MafB expression [Smink et al., 2009].
The effect of Epo on non-hematopoietic tissues remains
controversial. Recent work demonstrated that EpoR may be
expressed by a number of tumor cell lines and as a result the use
of Epo in the tumor setting has been questioned [Acs et al., 2001;
Henke et al., 2006; Jelkmann et al., 2008]. However, the expression
of EpoR in tumor tissues has been heavily dependent on the
detection methods and which reagents are used [Jelkmann et al.,
2008]. Epo receptors have also been found in several non-
hematopoietic tissues including neural, reproductive, and cardiac
systems [Arcasoy, 2010]. Epo also plays a protective role in a
number of tissues and situations [Gorio et al., 2002; Calvillo et al.,
2003; Bianchi et al., 2004; Grasso et al., 2004]. As such, EpoR
expression has been shown to induce proliferation of muscle,
intestine, and cardiomyocytes [Celik et al., 2002; Calvillo et al.,
2003; Brines and Cerami, 2005]. In fact, several types of vascular
endothelial cells have been shown to express EpoR [Anagnostou
et al., 1990; Yamaji et al., 1996] and Epo is able to stimulate
angiogenesis [Anagnostou et al., 1990]. EpoR expression in
neuronal cells [Masuda et al., 1993] and brain capillary endothelial
cells [Yamaji et al., 1996] suggests that Epo plays a role in
neuroprotection.
Fig. 4. Rapamycin inhibits Epo-dependent and -independent osteoclastogenesis in Raw264.7 cells. Raw264.7 cells were treated with Epo and/or rapamycin while cultured in
media with/without RANKL (or RL). After 1 week, TRAP staining was performed. A: Representative micrographs of TRAP-positive osteoclast. Original magniﬁcation at 20. B:
The numbers of TRAP-positive osteoclast were scored. The results represent average values from triplicate assays and the experiments were performed twice. C: Representative
micrographs of bone resorption. Original magniﬁcation at 20. D: Resorption area from ﬁve randomly selected ﬁelds was quantiﬁed using Image J software.
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In bone the effects are also controversial. In rodent models,
bleeding stimulates bone formation in addition to hematopoietic
activities [Foldes et al., 1989; Bab and Einhorn, 1993; Lucas et al.,
1997; Brager et al., 2000]. However, most of the investigation in this
area has focused on how bone tissue adapts to states of
hematopoietic stress where expanded hematopoietic activities
have been known to be associated with the conversion of fatty
marrow to hematopoietic marrow at the expense of bone. Likewise,
osteoporosis is a common ﬁnding in b-thalassemia, and bone
mineral densities are improved in transfused individuals [Yazigi
et al., 2002]. In contrast, Domracheva et al. [1985] reported that an
acute change in altitude, and by inference Epo, may increase MSC
numbers in patients with cytolytic syndromes. They noted that
ﬁbroblastic colony-formation was 2–4 times increased after altitude
change of 3,200m [Domracheva et al., 1985].
The effects of hormones are often organ and/or dose-dependent.
Parathyroid hormone (PTH), for example, initially was identiﬁed on
the basis of its ability to stimulate bone resorption. However, more
recent ﬁndings have moved PTH into the clinic as an anabolic bone
agent even though it appears to signal via the same receptor
[Bashutski et al., 2010]. Thus, it is very likely that Epo may also have
both anabolic and catabolic actions in bone depending on the
models used, dosing and skeletal site examined. As a case in point,
Singbrant et al. [2011] recently demonstrated an interaction
between erythropoiesis and skeletal homeostasis based on the
activation of osteoclasts but did not ﬁnd direct effects on
osteoblasts, their precursors, or HSCs. Moreover, it was demonstrat-
ed that the expression of EpoR is limited to cells of the erythoroid
lineage using lineage-tracing methods [Singbrant et al., 2011].
These ﬁndings suggest that osteoclasts or their immediate precursors
are of erythroid origin, yet there is little support in the literature nor
are osteoclasts depleted in aplastic anemia [Flanagan, 1990]. In
contrast, we have showed that HSCs express low levels of EpoR
using antibodies and quantitative RT-PCR, and HSCs respond to Epo
by inducing BMP expression via JAK/STAT signaling [Shiozawa et
al., 2010]. We also found that supra-physiologic doses of Epo
stimulated bone formation in the vertebral spines of neonatal and
young mice, while modestly increasing the hematocrit (4,500–
6,000U/kg, three times/week for 4 weeks) [Shiozawa et al., 2010].
Consistent with our results, a separate group has demonstrated that
Epo improves fracture healing in long bones [Lee et al., 1991].
In summary, the current work further elucidates the signaling
pathway that contributes to the direct effects of Epo on the
differentiation of osteoblasts and osteoclasts. We demonstrate
that the mTOR pathway is intimately involved in Epo-induced
osteogenesis and substantiates recent work that shows that mTOR
signaling is important for both osteoblastogenesis and osteoclas-
togenesis. Our results suggest that mTOR signaling is important for
Epo-dependent and -independent bone formation (Fig. 6).
Fig. 5. EPO and rapamycin increase NFATc1 expression and decrease cathep-
sin K expression. RAW264.7 cells were treated for 5 days with Epo and/or
rapamycin while cultured in media with/without RANKL (or RL). Induction of
the indicated genes was quantiﬁed by qPCR (A,B). The results were normalized
to b-actin. The results represent average values from duplicate assays and the
experiments were performed twice.
Fig. 6. Model for the role of mTOR signaling in Epo-mediated bone forma-
tion. Epo directly or indirectly (by inducing BMP expression from hematopoi-
etic stem cells—HSCs) induces osteoblast differentiation of mesenchymal stem
cells (MSCs) and mTOR inhibition by rapamycin blocks Epo-dependent and -
independent osteoblast differentiation. Epo also increases the number of
osteoclasts by up-regulation of NFATc1 while at the same time decreases
their activity by down-regulation of cathepsin K in an mTOR-independent
manner. Taken together, these results strongly indicate that mTOR signaling
plays an important role in Epo-dependent and -independent bone formation.
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